60
Participants
Start Date
December 31, 2007
Primary Completion Date
May 31, 2011
Study Completion Date
December 31, 2011
IPI-504, docetaxel
"1. IPI-504 administered IV at a dose of 300mg/m2~2. Docetaxel at a fixed dose of 75 mg/m2 for every 3 weeks dose administration or 36 mg/m2 for weekly administration"
Memorial Sloan-Kettering Cancer Center, New York
Roswell Park Cancer Institute, Buffalo
University of Pittsburgh Medical Center, Pittsburgh
H. Lee Moffitt Cancer Center & Research Institute, Tampa
Gabrail Cancer Center, Dover
Gabrail Cancer Center, Canton
TGen Clinical Research in Scottsdale, Scottsdale
Yale Cancer Center, New Haven
Lead Sponsor
Infinity Pharmaceuticals, Inc.
INDUSTRY